Sir,
Mytonic dystrophy type 1 (DM1) is an autosomal dominant disorder caused by mutation in the dystrophia myotonica protein kinase (DMPK) gene, located on chromosome 19 (19q13.2–q13.3). Ocular findings reported to date include colored iridescent cataract, strabismus, and limitation of extraocular muscle movement, ptosis, and rarely macular dystrophy.1
Case report
A 21-year-old male with DM1 presented with a 4-week history of deteriorating vision in his left eye, assumed to be cataract. Clinical examination, however, showed bilateral pattern dystrophy (Figure 1a) with best corrected visual acuity (VA) recorded at 6/6 in the right eye and 6/15 in the left eye, which had choroidal new vessels (CNVs) (Figures 1b and 2aI). Treatment followed consent of the off-label nature of intravitreal bevacizumab (IVB). After 4 weeks, symptoms had improved but due to persisting intraretinal fluid (Figure 2aII) a second IVB injection was given. After 4 weeks, VA had improved to 6/7.5 with both OCT and angiography confirming no leakage (Figures 2aIII and b). No recurrence was seen at most recent follow-up 14 months later. His father who had DM1 was also examined, but did not have macular dystrophy.
Comment
To our knowledge this is the first report of CNVs complicating DM1. The cause of the macular phenotype is still unknown. The expansion of CTG triplet repeats in DM1 arise within the 3’ untranslated region of the DMPK gene,2, 3 but this region also overlaps downstream with the promoter of the homeobox gene SIX5 on chromosome 19q13.3.4 As expression of this gene has been localized to the lens, retina, and choroid, it has been proposed that SIX5 and not DMPK is responsible for the ocular phenotype of DM.5 The non-penetrant inheritance of the macular dystrophy, might either indicate a digenic pattern where transcriptional silencing of the SIX5 gene through expansion of CTG repeats occurs from one generation to the next through anticipation or it might indicate variable expressivity. Beyond the genetics, our observations show that deterioration of VA in patients with DM can be due to macular dystrophy and, rarely, CNVs. The rapid response to IVB provides evidence that VEGF has a role in this disease.
References
Hayasaka S, Kiyosawa M, Katsumata S, Honda M, Takase S, Mizuno K . Ciliary and retinal changes in myotonic dystrophy. Arch Ophthalmol 1984; 102: 88–93.
Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 68: 799–808.
Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992; 255: 1253–1255.
Thornton CA, Wymer JP, Simmons Z, McClain C, Moxley RT . Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nat Genet 1997; 16: 407–409.
Winchester CL, Ferrier RK, Sermoni A, Clark BJ, Johnson KJ . Characterization of the expression of DMPK and SIX5 in the human eye and implications for pathogenesis in myotonic dystrophy. Hum Mol Genet 1999; 8: 481–492.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Zinkernagel, M., Hornby, S. & MacLaren, R. Choroidal new vessels in type 1 myotonic dystrophy-related macular dystrophy respond to anti-VEGF therapy. Eye 26, 1595–1596 (2012). https://doi.org/10.1038/eye.2012.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2012.197
This article is cited by
-
Polypoidal choroidal vasculopathy in a patient with DMPK-associated myotonic dystrophy
Documenta Ophthalmologica (2022)